 Connection
Matthew Ellis to Opioid-Related Disorders
This is a "connection" page, showing publications Matthew Ellis has written about Opioid-Related Disorders.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.980 |
|
|
|
-
Marks LR, Durkin MJ, Ayres K, Ellis M. Drug preparation, injection-related infections, and harm reduction practices among a national sample of individuals entering treatment for opioid use disorder. Harm Reduct J. 2024 01 19; 21(1):16.
Score: 0.451
-
Jewell JS, Rockhill KM, Burkett H, Black JC, Ellis MS, Dart R. Trends in XTAMPZA ER and other oxycodone misuse and abuse during COVID-19: A mosaic approach. J Opioid Manag. 2025 May-Jun; 21(3):249-259.
Score: 0.123
-
Bredenberg E, Olsen H, Ladka M, Beekman K, Black JC, Ellis MS, Monte AA. People entering opioid substance use treatment have low rates of naloxone knowledge and possession. Drug Alcohol Depend. 2025 Jun 01; 271:112645.
Score: 0.122
-
Severtson SG, Gurrola MC, Parrino MW, Ellis MS, Cicero TJ, Iwanicki JL, Dart RC. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders. J Opioid Manag. 2023 Sep-Oct; 19(5):445-453.
Score: 0.110
-
Jewell J, Black J, Ellis M, Olsen H, Iwanicki J, Dart R. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population. Clin Drug Investig. 2023 Mar; 43(3):197-203.
Score: 0.106
-
Iwanicki JL, Severtson SG, McDaniel H, Rosenblum A, Fong C, Cicero TJ, Ellis MS, Kurtz SP, Buttram ME, Dart RC. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States. PLoS One. 2016; 11(12):e0167499.
Score: 0.069
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|